SHR2554 combined with other cancer drugs for advanced non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II, open-label interventional study enrolls adults (18–75 years) with pathologically confirmed locally advanced unresectable or metastatic NSCLC and ECOG 0–1. Participants receive oral SHR2554 combined with one of several partner anti-tumor agents (for example SHR-A2102, adabelimumab, or SHR-1701) and are monitored for safety, tolerability, and objective tumor response by imaging at scheduled visits. Key exclusions include symptomatic or active central nervous system metastases, other active malignancies, inability to swallow or malabsorption issues, recent anti-cancer therapy within 4 weeks, uncontrolled tumor-related pain, or spinal cord compression not amenable to treatment. Primary endpoints include safety, tolerability, and objective response rate with routine lab tests and radiographic assessments to track responses and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range of 18-75 years old (including both ends), gender not limited;
2. Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology
3. ECOG score is 0 or 1
4. Expected survival period ≥ 12 weeks
5. Has a good level of organ function
6. Patients voluntarily joined the study and signed informed consent

Exclusion Criteria:

1. Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
2. Symptomatic or active central nervous system tumor metastasis
3. Previously or simultaneously suffering from other malignant tumors
4. Spinal cord compression that cannot be cured by surgery and/or radiotherapy
5. Accompanied by uncontrolled tumor related pain
6. Plan to receive any other anti-tumor treatment during this trial period
7. Receive other anti-tumor treatments within 4 weeks before the first medication
8. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration
9. Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
10. Moderate to severe pleural effusion with clinical symptoms
11. Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
12. Subjects who have experienced severe infections within 30 days prior to their first medication use
13. Administer attenuated live vaccine within 30 days before the first use of medication.
14. History of immunodeficiency
15. Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
16. History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
17. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1
18. Untreated active hepatitis
19. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
20. There are other serious physical or mental illnesses or laboratory abnormalities present

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xiaoxue Pi
• Email: Xiaoxue.pi@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating AST2303 Tablets in Patients with Advanced Lung Cancer

  This study is testing if AST2303 tablets are safe and effective for people with advanced non-small cell lung cancer.

  Recruiting Phase 1 Allist Pharmaceuticals, Inc. · Shanghai, Shanghai Municipality · NCT06955988

• XZP-5955 tablets for patients with specific advanced solid tumors

  This study is testing if XZP-5955 tablets can help patients with advanced solid tumors that have specific gene changes, especially those who have run out of other treatment options.

  Recruiting Phase 1/2 Xuanzhu Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT04996121

• Safety of T-DXd with Immunotherapy in Advanced HER2+ Lung Cancer

  This study is testing if a new combination of a drug called T-DXd with immunotherapy and chemotherapy is safe for people with advanced HER2-positive lung cancer.

  Recruiting at 47 sites Phase 1 AstraZeneca · Duarte, California and 90 other locations · NCT04686305

• Evaluating PF-07248144 for advanced solid tumors

  This study is testing a new drug called PF-07248144 to see if it can safely help people with advanced solid tumors, like certain types of breast, prostate, and lung cancers.

  Recruiting at 40 sites Phase 2 Pfizer · Scottsdale, Arizona and 42 other locations · NCT04606446

• Osimertinib-based adaptive treatment guided by ctDNA EGFR mutation monitoring for advanced EGFR-mutant NSCLC

  This Phase 2 trial tests whether using blood ctDNA to guide when to continue or step down osimertinib (with or without chemotherapy) can keep cancer controlled while reducing treatment side effects for people with advanced EGFR-mutant non-small cell lung cancer who clear EGFR mutations from plasma after initial therapy

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07058519

• ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers

  This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.

  Recruiting at 6 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France and 6 other locations · NCT07483983

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.